Title:The Anticancer Activity of Complex [Cu2(μ-(C6H5)2CHCOO)3(bipy)2)] (ClO4) -Solid Lipid Nanoparticles on MCF-7 Cells
Volume: 13
Issue: 8
Author(s): Ibrahim Kani, Gokhan Dikmen, Gamze Guney Eskiler, Gulsah Cecener, Berrin Tunca and Unal Egeli
Affiliation:
Keywords:
Bipy, Cu(II) complex, diphenyl acetic acid, MCF-7, metal-based ligands, solid lipid nanoparticles(SLNs).
Abstract: Recent studies have focused on the potential use of metal-based complexes for the treatment
of cancer. However, there are some limitations of metal-based ligands for the treatment of cancer due to
their toxic effects. In the present study, a novel bimetallic Cu(II) complex, [Cu2(μ-(C6H5)2CHCOO)3
(bipy)2)](ClO4), has firstly been synthesized and characterized by FT-IR, and X-ray crystallography.
Furthermore, Cu(II) complex-loaded solid lipid nanoparticles (SLNs) were initially prepared by hot
homogenization method to overcome their toxic effects. After characterization, comparative cytotoxic
and apoptotic activities of the complex and Cu(II) complex-SLNs on human breast cancer cells (MCF-7)
and human umbilical vein endothelial cells (HUVEC) were determined. Cu(II) complex demonstrated
considerable in vitro cytotoxic effects on MCF-7 (p<0.05) and induced apoptotic cell death (88.02 ±
3.95%) of MCF-7 cells. But, the complex has also toxic effects (69.5%) on HUVEC control cells. For
this purpose, Cu(II) complex-loaded solid lipid nanoparticles (SLN) were firstly produced, with a distrubution
range of 190±1.45 nm to 350±1.72 nm and zeta potentials of −27.4±1.98 mV and −18.2±1.07
mV, respectively. The scanning electron microscopy (SEM) images of SLNs were also obtained. In
vitro studies have shown that Cu(II) complex-SLNs help in reducing the side effect of Cu(II) complex
(29.9%) on HUVEC control cells. Therefore, metal based complex might potentially be used for cancer
treatment through nanoparticle based drug delivery systems.
